Contineum Therapeutics (CTNM) completed the enrollment of 168 patients in its phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis.

The trial is designed to assess safety and efficacy by evaluating multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients, the company said. The last patient is expected to complete the trial by Q3.

PIPE-307 is being developed under a global license and development agreement between Continuum and Janssen Pharmaceutica, a unit of Johnson & Johnson (JNJ).